An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth

被引:14
作者
Crowder, C
Kopantzev, E
Williams, K
Lengel, C
Miki, T
Rudikoff, S [1 ]
机构
[1] NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA
[2] NCI, Mol Tumor Biol Sect, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Ras; mutation; transformation; growth factor independence;
D O I
10.1038/sj.onc.1206180
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple myeloma (MM) is an incurable plasma cell malignancy. To investigate biochemical lesions associated,with MM, we constructed an expression cDNA library from the OPM-2 human myeloma line. A highly transforming H-Ras mutant was identified by transfection analysis using NIH 3T3 cells. DNA sequencing demonstrated a single-point mutation at position 117 located in the guanine nucleotide-binding site resulting in a lysine-to-glutamic acid substitution. This mutant, H-Ras (K117E), was found to be constitutively activated in terms of GTP binding. We compared the biological effects of H-Ras (K117E) and H-Ras (G12V) in 32D murine hematopoietic progenitor cells. Whereas both Ras proteins are constitutively activated, 32D cells expressing H-Ras (G12V) are still dependent on IL-3 for survival and proliferation while cells carrying H-Ras (K117E) become IL-3 independent. Similar experiments conducted with the B9 line, an IL-6-dependent hybridoma, also demonstrated that B9/H-Ras (KI17E) became IL-6-independent. Expression of H-Ras (K117E) in the human IL-6-dependent ANBL-6 myeloma line resulted in enhanced proliferation at suboptimal concentrations of IL-6. These observations suggest that H-Ras mutations at the binding site for the GTP nucleotide ring structure may also represent activating lesions and have additional biological effects when compared to previously described Ras mutants.
引用
收藏
页码:649 / 659
页数:11
相关论文
共 56 条
[1]   RAS PROTOONCOGENE ACTIVATION IN DICHLOROACETIC ACID-INDUCED, TRICHLOROETHYLENE-INDUCED AND TETRACHLOROETHYLENE-INDUCED LIVER-TUMORS IN B6C3F1 MICE [J].
ANNA, CH ;
MARONPOT, RR ;
PEREIRA, MA ;
FOLEY, JF ;
MALARKEY, DE ;
ANDERSON, MW .
CARCINOGENESIS, 1994, 15 (10) :2255-2261
[2]   Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma [J].
Bergsagel, PL ;
Chesi, M ;
Nardini, E ;
Brents, LA ;
Kirby, SL ;
Kuehl, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :13931-13936
[3]   INTERLEUKIN-3 AND INTERLEUKIN-6 SYNERGISTICALLY PROMOTE THE PROLIFERATION AND DIFFERENTIATION OF MALIGNANT PLASMA-CELL PRECURSORS IN MULTIPLE-MYELOMA [J].
BERGUI, L ;
SCHENA, M ;
GAIDANO, G ;
RIVA, M ;
CALIGARISCAPPIO, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (02) :613-618
[4]   High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis [J].
Bezieau, S ;
Devilder, MC ;
Avet-Loiseau, H ;
Mellerin, MP ;
Puthier, D ;
Pennarun, E ;
Rapp, MJ ;
Harousseau, JL ;
Moisan, JP ;
Bataille, R .
HUMAN MUTATION, 2001, 18 (03) :212-224
[5]  
Billadeau D, 1997, CANCER RES, V57, P2268
[6]  
BILLADEAU D, 1995, CANCER RES, V55, P3640
[7]  
BOS JL, 1987, BLOOD, V69, P1237
[8]   Recurrent immunoglubulin gene translocations identify distinct molecular subtypes of myeloma [J].
Chesi, M ;
Kuehl, WM ;
Bergsagel, PL .
ANNALS OF ONCOLOGY, 2000, 11 :131-135
[9]   Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma [J].
Chesi, M ;
Brents, LA ;
Fly, SA ;
Bais, C ;
Robbiani, DF ;
Mesri, E ;
Kuehl, WM ;
Bergsagel, PL .
BLOOD, 2001, 97 (03) :729-736
[10]   MUTATIONS OF THE RAS GENE-PRODUCT P21 THAT ABOLISH GUANINE-NUCLEOTIDE BINDING [J].
CLANTON, DJ ;
HATTORI, S ;
SHIH, TY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (14) :5076-5080